What are the major opportunities in the Nuvaxovid market? What are the strategies for the Nuvaxovid market?

For detailed insights on the major opportunities and strategies in the Nuvaxovid market, Read More

How does the Nuvaxovid market relate to the overall economy and other similar markets?

For detailed insights on Nuvaxovid's relation to the overall economy and other similar markets, Read More

What are the latest mergers and acquisitions in the Nuvaxovid industry?

For detailed insights on the mergers and acquisitions in the Nuvaxovid industry, Read More

What are the key dynamics influencing the Nuvaxovid market growth? SWOT analysis of the Nuvaxovid market.

For detailed insights on the key dynamics influencing the Nuvaxovid market growth and SWOT analysis of the Nuvaxovid industry, Read More

Item added to cart!

Published : December 2025

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Nuvaxovid Global Market Report 2025

Name: Nuvaxovid Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Clinical Indication (Primary Immunization, Booster Immunization, Immunocompromised Patients, Elderly Population, Pediatric Immunization, Travel Immunization), By End Use (Hospitals, Clinics, Ambulatory Care, Home Care), By Distribution Channel (Retail Pharmacies, Online Sales, Government Programs)

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Nuvaxovid Market?

Nuvaxovid is a protein-based vaccine that uses recombinant spike protein from the SARS-CoV-2 virus combined with an adjuvant (Matrix-M) to enhance the immune response. It stimulates the immune system to recognize and fight the virus, protecting against COVID-19. Nuvaxovid is administered as a two-dose series and is authorized in various countries to prevent COVID-19 in individuals aged 12 and older.

The main utilizations of the nuvaxovid are primary immunization, booster immunization, immunocompromised patients, elderly populations, pediatric immunization, and travel immunization. Primary immunization is the initial series of vaccine doses administered to stimulate and establish long-term immunity against specific infectious diseases. It is used by the hospitals, clinics, ambulatory care, and home care. nuvaxovid is distributed through channels such as Retail pharmacies, online sales, and government programs.

Nuvaxovid Market Size and growth rate 2025 to 2029: Graph

What Is The Nuvaxovid Market Size 2025 And Growth Rate?

The nuvaxovid market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased global vaccination rates, increased regulatory approvals, increased research funding, a rise in infection rates, and increased awareness of vaccine benefits.

What Is The Nuvaxovid Market Growth Forecast?

The nuvaxovid market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to increasing global demand for COVID-19 vaccines, rising investments in vaccine manufacturing capacities, growing demand for travel-related immunizations, rising income levels driving vaccine purchases, and an increase in online platforms for vaccine orders. Major trends in the forecast period include innovations in vaccine delivery methods, innovations in vaccine cold-chain logistics, partnerships with pharmaceutical companies for regional supply, technological advancements in vaccine production, and advancements in vaccine storage technology.

Book your 30 minutes free consultation with our research experts

How Is The Nuvaxovid Market Segmented?

The nuvaxovid market covered in this report is segmented –

1) By Clinical Indication: Primary Immunization; Booster Immunization; Immunocompromised Patients; Elderly Population; Pediatric Immunization; Travel Immunization

2) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care

3) By Distribution Channel: Retail Pharmacies; Online Sales; Government Programs

What Is Driving The Nuvaxovid Market? Rising Infectious Diseases And COVID-19 Prevalence Boost The Market

The rising prevalence of infectious diseases is expected to drive the growth of the nuvaxovid market going forward. Infectious diseases are illnesses caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, that spread from person to person or through the environment. The rise in infectious diseases is fueled by global travel, urbanization, climate change, antimicrobial resistance, and the emergence of new pathogens, all contributing to their growing prevalence. Nuvaxovid contributes to addressing the rise in the prevalence of infectious diseases by providing an effective vaccine to prevent COVID-19 and reduce transmission, helping to curb the spread of the virus globally. For instance, in March 2023, according to the Office for National Statistics, a UK-based government agency, COVID-19 infections increased in England, with an estimated 2.66% of the population testing positive (1 in 40 people) during the week ending 13 March 2023, while trends were uncertain in Wales (2.41%, 1 in 40), Scotland (2.59%, 1 in 40), and Northern Ireland (1.42%, 1 in 70). The infection rate rose in the North West, East Midlands, and South East, affecting age groups from 2 years to school Year 11 and those aged 50 and over, with hospital admissions for confirmed COVID-19 in England rising to 10.62 per 100,000 people by the week ending 19 March 2023, and 619 COVID-19-related deaths in the UK by the week ending 17 March 2023, up from 605 the previous week. Therefore, the rising prevalence of infectious diseases is driving the nuvaxovid market.

What Is Driving The Nuvaxovid Market? Rising Vaccine Demand Drives Market Growth For Updated COVID-19 Vaccines

The increase in vaccine demand is expected to drive the growth of the nuvaxovid market going forward. Vaccines are biological substances that stimulate the immune system, enabling the body to recognize and fight specific infectious diseases. The demand for vaccines is increasing due to the rise in infectious diseases, greater public awareness of health protection, advancements in vaccine development, and the growing focus on preventive healthcare. Nuvaxovid addresses the rising vaccine demand by providing an updated solution targeting emerging COVID-19 variants, ensuring broader protection, and supporting global immunization efforts. For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, by October 2024, 13.7% of U.S. adults aged 18 and older had received the 2024–25 COVID-19 vaccine, while 24.5% had received the flu vaccine for the same season. Vaccination rates were highest among those aged 65 and older, with 29.1% receiving COVID-19 and 43.1% the flu vaccine. Therefore, the increase in demand for vaccines is driving the nuvaxovid market.

Who Are The Major Players In The Global Nuvaxovid Market?

Major companies operating in the nuvaxovid market are Novavax Inc.

What Are The Key Trends Of The Global Nuvaxovid Market? Updated Vaccine Targets Emerging COVID-19 Variants Enhancing Global Vaccination Efforts

The key trend in the nuvaxovid market is developing innovative vaccine delivery systems, such as updated COVID-19 vaccines, to provide an effective solution for preventing COVID-19 and addressing emerging variants, enhancing global vaccination efforts. An updated COVID-19 vaccine is a modified version of the original vaccine designed to improve protection against newly circulating variants of the SARS-CoV-2 virus, ensuring continued effectiveness in preventing severe illness and hospitalization. For instance, in October 2024, Novavax, Inc., a US-based biotechnology company, announced that the European Commission granted marketing authorization for Novavax's updated 2024-2025 Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) for individuals aged 12 and older to prevent COVID-19 in the European Union. The updated vaccine targets the JN.1 lineage and provides cross-reactivity against several other variants. This approval is significant as it expands access to an updated vaccine formulation to address emerging COVID-19 variants and supports ongoing global vaccination efforts.

Need data on a specific region in this market?

Request Regional Data

Regional Analysis For The Global Nuvaxovid Market

North America was the largest region in the nuvaxovid market in 2024. The regions covered in the nuvaxovid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuvaxovid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Nuvaxovid Market?

The nuvaxovid market consists of sales of nuvaxovid multidose vial and the single dose. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Nuvaxovid Industry?

The nuvaxovid market research report is one of a series of new reports from The Business Research Company that provides nuvaxovid market statistics, including nuvaxovid industry global market size, regional shares, competitors with nuvaxovid market share, detailed nuvaxovid market segments, market trends and opportunities, and any further data you may need to thrive in the nuvaxovid industry. This nuvaxovid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Author : Abhilash Pyata

Nuvaxovid Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	Included ?
Revenue Forecast In 2034	Included ?
Growth Rate	Included ?
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The nuvaxovid market covered in this report is segmented – 1) By Clinical Indication: Primary Immunization; Booster Immunization; Immunocompromised Patients; Elderly Population; Pediatric Immunization; Travel Immunization 2) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care 3) By Distribution Channel: Retail Pharmacies; Online Sales; Government Programs
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Novavax Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Nuvaxovid Market Characteristics

3. Nuvaxovid Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route Of Administration (ROA)

3.3. Mechanism Of Action (MOA)

3.4. Safety And Efficacy

4. Nuvaxovid Market Trends And Strategies

5. Nuvaxovid Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

6. Global Nuvaxovid Growth Analysis And Strategic Analysis Framework

6.1. Global Nuvaxovid PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis Of End Use Industries

6.3. Global Nuvaxovid Market Growth Rate Analysis

6.4. Global Nuvaxovid Historic Market Size and Growth, 2019 - 2024, Value ($ Million)

6.5. Global Nuvaxovid Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)

6.6. Global Nuvaxovid Total Addressable Market (TAM)

7. Global Nuvaxovid Pricing Analysis & Forecasts

8. Nuvaxovid Market Segmentation

8.1. Global Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Primary Immunization

Booster Immunization

Immunocompromised Patients

Elderly Population

Pediatric Immunization

Travel Immunization

8.2. Global Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Hospitals

Clinics

Ambulatory Care

Home Care

8.3. Global Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Retail Pharmacies

Online Sales

Government Programs

9. Global Nuvaxovid Epidemiology Of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence And Prevalence of Clinical Indications

10. Nuvaxovid Market Regional And Country Analysis

10.1. Global Nuvaxovid Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

10.2. Global Nuvaxovid Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Nuvaxovid Market

11.1. Asia-Pacific Nuvaxovid Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.3. Asia-Pacific Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.4. Asia-Pacific Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Nuvaxovid Market

12.1. China Nuvaxovid Market Overview

12.2. China Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.3. China Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.4. China Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Nuvaxovid Market

13.1. India Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.2. India Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.3. India Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Nuvaxovid Market

14.1. Japan Nuvaxovid Market Overview

14.2. Japan Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.3. Japan Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.4. Japan Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Nuvaxovid Market

15.1. Australia Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.2. Australia Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.3. Australia Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Nuvaxovid Market

16.1. South Korea Nuvaxovid Market Overview

16.2. South Korea Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.3. South Korea Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.4. South Korea Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Nuvaxovid Market

17.1. Western Europe Nuvaxovid Market Overview

17.2. Western Europe Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.3. Western Europe Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.4. Western Europe Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Nuvaxovid Market

18.1. UK Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.2. UK Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.3. UK Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Nuvaxovid Market

19.1. Germany Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.2. Germany Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.3. Germany Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Nuvaxovid Market

20.1. France Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.2. France Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.3. France Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Nuvaxovid Market

21.1. Eastern Europe Nuvaxovid Market Overview

21.2. Eastern Europe Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.3. Eastern Europe Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.4. Eastern Europe Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Nuvaxovid Market

22.1. North America Nuvaxovid Market Overview

22.2. North America Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.3. North America Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.4. North America Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Nuvaxovid Market

23.1. USA Nuvaxovid Market Overview

23.2. USA Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.3. USA Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.4. USA Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Nuvaxovid Market

24.1. Canada Nuvaxovid Market Overview

24.2. Canada Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.3. Canada Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.4. Canada Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Nuvaxovid Market

25.1. South America Nuvaxovid Market Overview

25.2. South America Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.3. South America Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.4. South America Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Nuvaxovid Market

26.1. Middle East Nuvaxovid Market Overview

26.2. Middle East Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.3. Middle East Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.4. Middle East Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Nuvaxovid Market

27.1. Africa Nuvaxovid Market Overview

27.2. Africa Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.3. Africa Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.4. Africa Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Nuvaxovid Market Competitive Landscape And Company Profiles

28.1. Nuvaxovid Market Competitive Landscape

28.2. Nuvaxovid Market Company Profiles

28.2.1. Novavax Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Nuvaxovid Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Nuvaxovid Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Nuvaxovid Market

32. Recent Developments In The Nuvaxovid Market

33. Nuvaxovid Market High Potential Countries, Segments and Strategies

33.1 Nuvaxovid Market In 2029 - Countries Offering Most New Opportunities

33.2 Nuvaxovid Market In 2029 - Segments Offering Most New Opportunities

33.3 Nuvaxovid Market In 2029 - Growth Strategies

33.3.1 Market Trend Based Strategies

33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations

34.2. Currencies

34.3. Historic And Forecast Inflation Rates

34.4. Research Inquiries

34.5. The Business Research Company

34.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Million

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Table 3: Global Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 4: Global Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 5: Global Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 6: Global Nuvaxovid Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 7: Global Nuvaxovid Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 8: Asia-Pacific, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 9: Asia-Pacific, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 10: Asia-Pacific, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 11: China, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 12: China, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 13: China, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 14: India, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 15: India, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 16: India, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 17: Japan, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 18: Japan, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 19: Japan, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 20: Australia, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 21: Australia, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 22: Australia, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 23: South Korea, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 24: South Korea, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 25: South Korea, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 26: Western Europe, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 27: Western Europe, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 28: Western Europe, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 29: UK, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 30: UK, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 31: UK, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 32: Germany, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 33: Germany, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 34: Germany, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 35: France, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 36: France, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 37: France, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 38: Eastern Europe, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 39: Eastern Europe, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 40: Eastern Europe, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 41: North America, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 42: North America, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 43: North America, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 44: USA, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 45: USA, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 46: USA, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 47: Canada, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 48: Canada, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 49: Canada, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 50: South America, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 51: South America, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 52: South America, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 53: Middle East, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 54: Middle East, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 55: Middle East, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 56: Africa, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 57: Africa, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 58: Africa, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 59: Novavax Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Million

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Figure 3: Global Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 4: Global Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 5: Global Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 6: Global Nuvaxovid Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 7: Global Nuvaxovid Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 8: Asia-Pacific, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 9: Asia-Pacific, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 10: Asia-Pacific, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 11: China, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 12: China, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 13: China, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 14: India, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 15: India, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 16: India, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 17: Japan, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 18: Japan, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 19: Japan, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 20: Australia, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 21: Australia, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 22: Australia, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 23: South Korea, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 24: South Korea, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 25: South Korea, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 26: Western Europe, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 27: Western Europe, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 28: Western Europe, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 29: UK, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 30: UK, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 31: UK, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 32: Germany, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 33: Germany, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 34: Germany, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 35: France, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 36: France, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 37: France, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 38: Eastern Europe, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 39: Eastern Europe, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 40: Eastern Europe, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 41: North America, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 42: North America, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 43: North America, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 44: USA, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 45: USA, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 46: USA, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 47: Canada, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 48: Canada, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 49: Canada, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 50: South America, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 51: South America, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 52: South America, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 53: Middle East, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 54: Middle East, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 55: Middle East, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 56: Africa, Nuvaxovid Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 57: Africa, Nuvaxovid Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 58: Africa, Nuvaxovid Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 59: Novavax Inc. Financial Performance

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Anesthesia And Respiratory Devices Market 2021 - By Type (Respiratory Devices, Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables), By Expenditure (Public Expenditure, Private Expenditure), By Gender (M...

Pharmaceutical Drugs And Biologics Logistics Market 2021 - By Type Of Service (Cold Chain Logistics, Non-Cold Chain Logistics), By Mode Of Transport (Air Transportation, Ocean Transportation, Land Transportation), By Pha...

Respiratory Devices And Equipment (Therapeutic And Diagnostic) Global Market Report 2025 – By Type (Diagnostic devices, Therapeutic devices, Monitoring devices), By Therapeutic Devices (Humidifiers, Nebulizers, Oxygen co...

Respiratory Disposables Global Market Report 2025 – By Type (Masks, Tubes, Inhalers, Other Types), By Disease Indications (Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respirat...

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2025 – By Product (Nebulizers, Humidifiers, Oxygen Concentrators, Positive Airway Pressure Devices, Ventilators, Capnographs, Gas Analyzers), By Techno...

Respiratory Monitoring Devices Global Market Report 2025 – By Type (Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs, Others Types), By Application (Chronic Obstructive Pulmonar...

Respiratory Devices And Equipment (Diagnostic) Global Market Report 2025 – By Product (Instruments And Devices, Assays And Reagents), By Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular...

Frequently Asked Questions

What is the definition of the Nuvaxovid market?

How will the Nuvaxovid market drivers and restraints affect the market dynamics? What forces will shape the Nuvaxovid industry going forward?

The Nuvaxovid market major growth driver - Rising Infectious Diseases And COVID-19 Prevalence Boost The Market. For further insights on the Nuvaxovid market, request a sample here

What is the forecast market size or the forecast market value of the Nuvaxovid market?

The Nuvaxovid market size has grown strongly in recent years. The nuvaxovid market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased global vaccination rates, increased regulatory approvals, increased research funding, a rise in infection rates, and increased awareness of vaccine benefits. The nuvaxovid market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to increasing global demand for COVID-19 vaccines, rising investments in vaccine manufacturing capacities, growing demand for travel-related immunizations, rising income levels driving vaccine purchases, and an increase in online platforms for vaccine orders. Major trends in the forecast period include innovations in vaccine delivery methods, innovations in vaccine cold-chain logistics, partnerships with pharmaceutical companies for regional supply, technological advancements in vaccine production, and advancements in vaccine storage technology. For further insights on the Nuvaxovid market, request a sample here

How is the Nuvaxovid market segmented?

The nuvaxovid market covered in this report is segmented –
1) By Clinical Indication: Primary Immunization; Booster Immunization; Immunocompromised Patients; Elderly Population; Pediatric Immunization; Travel Immunization
2) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
3) By Distribution Channel: Retail Pharmacies; Online Sales; Government Programs For further insights on the Nuvaxovid market, request a sample here

Which region has the largest share of the Nuvaxovid market? What are the other regions covered in the report?

Who are the major players in the Nuvaxovid market?

Major companies operating in the nuvaxovid market are Novavax Inc. . For further insights on the Nuvaxovid market, request a sample here.

What are the key trends in the Nuvaxovid market?

Major trends in the Nuvaxovid market include Updated Vaccine Targets Emerging COVID-19 Variants Enhancing Global Vaccination Efforts. For further insights on the Nuvaxovid market, request a sample here.